Get Premium to unlock powerful stock data
NAS:ASND (Denmark)  
Ascendis Pharma A/S logo

Ascendis Pharma A/S

$ 92.96 -1.24 (-1.32%) 04:00 PM EST
P/E:
At Loss
P/B:
7.05
Market Cap:
$ 5.19B
Enterprise V:
$ 4.73B
Volume:
312.40K
Avg Vol (2M):
553.42K
Also Trade In:
Volume:
312.40K
Market Cap $:
5.19B
PE Ratio:
At Loss
Avg Vol (2-Month):
553.42K
Enterprise Value $:
4.73B
PB Ratio:
7.05
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Description
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Name Current Vs Industry Vs History
Cash-To-Debt 2.07
Equity-to-Asset 0.49
Debt-to-Equity 0.7
Debt-to-EBITDA -1.1
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.9
Distress
Grey
Safe
Beneish M-Score -1.52
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 70.69
9-Day RSI 63.54
14-Day RSI 57.77
6-1 Month Momentum % -33.61
12-1 Month Momentum % -33.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 11.76
Quick Ratio 10.79
Cash Ratio 10.26
Days Inventory 6557.34
Days Sales Outstanding 47.07
Days Payable 5505.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.6

Financials (Next Earnings Date:2022-08-25 Est.)

ASND's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ASND

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 15.595
EPS (TTM) ($) -9.287
Beta 0.92
Volatility % 45.52
14-Day RSI 57.77
14-Day ATR ($) 5.301165
20-Day SMA ($) 86.6265
12-1 Month Momentum % -33.87
52-Week Range ($) 61.5791 - 178.71
Shares Outstanding (Mil) 55.8

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ascendis Pharma A/S Filings

Document Form Filing Date
No Filing Data

Headlines

See More